Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | +0.73% | -1.32% | -12.90% |
Jan. 04 | Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates | CI |
Dec. 07 | Top Premarket Gainers | MT |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 15.26M |
---|---|---|---|---|---|
Net income 2023 * | -19M | Net income 2024 * | -22M | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.72
x | P/E ratio 2024 * |
-0.59
x | Employees | 12 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 69.97% |
1 day | +0.73% | ||
1 week | -1.32% | ||
Current month | +4.90% | ||
1 month | +3.49% | ||
3 months | -14.77% | ||
6 months | -23.47% | ||
Current year | -12.90% |
Managers | Title | Age | Since |
---|---|---|---|
Sam Lee
CEO | Chief Executive Officer | 64 | 14-01-01 |
James Martin
CEO | Chief Executive Officer | 58 | 17-02-22 |
Roger Kornberg
CHM | Chairman | 77 | 14-01-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Phillip Frost
BRD | Director/Board Member | 87 | 14-01-01 |
Director/Board Member | 68 | 21-05-26 | |
Steven Rubin
BRD | Director/Board Member | 63 | 14-01-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 1.5 | +0.73% | 11,756 |
24-03-26 | 1.489 | -0.72% | 7,185 |
24-03-25 | 1.5 | -1.96% | 8,274 |
24-03-22 | 1.53 | +1.32% | 4,944 |
24-03-21 | 1.51 | -0.66% | 13,369 |
Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.90% | 15.26M | |
+28.67% | 46.19B | |
+18.57% | 22.88B | |
+20.11% | 14.18B | |
-0.59% | 12.63B | |
+46.16% | 12.07B | |
-1.55% | 7.85B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+7.37% | 5.14B |